Pfizer, Merck, Regeneron: Covid Treatment Stocks Back In Focus As Infections Soar

Our indicative theme on Covid-19 Treatment Stocks - which includes biotech and pharma companies selling or developing treatments for the Covid-19 virus - is up by 25% year-to-date, compared to the S&P 500 which is up about 26% over the same period. Although we were somewhat circumspect about the...